Hutchison China MediTech Limited (NASDAQ:HCM) Getting Somewhat Favorable Media Coverage, Accern Reports
Media headlines about Hutchison China MediTech Limited (NASDAQ:HCM) have trended somewhat positive on Saturday, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hutchison China MediTech Limited earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.8217118443293 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Trade Signal Alert For Royal Bank of Scotland Group PLC (RBS.L) (campdesrecrues.com)
- Hutchison China MediTech Ltd. :HCM-US: Earnings Analysis: For the six months ended June 30, 2017 : August 7, 2017 (finance.yahoo.com)
- Hutchison China MediTech Limited (NASDAQ:HCM) Given $28.50 Consensus Price Target by Brokerages (americanbankingnews.com)
- Hutchison China Meditech Ltd. 2017 Q2 – Results – Earnings Call Slides (seekingalpha.com)
HCM has been the topic of a number of recent analyst reports. Canaccord Genuity set a $30.00 price objective on Hutchison China MediTech Limited and gave the company a “buy” rating in a research note on Tuesday, June 6th. Zacks Investment Research downgraded Hutchison China MediTech Limited from a “hold” rating to a “sell” rating in a research note on Monday, May 15th.
Shares of Hutchison China MediTech Limited (NASDAQ HCM) traded down 4.77% during mid-day trading on Friday, reaching $24.38. The company had a trading volume of 39,551 shares. Hutchison China MediTech Limited has a 12-month low of $10.61 and a 12-month high of $27.96.
Hutchison China MediTech Limited Company Profile
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.
Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.